Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm, the incidence of which increases with age. Tyrosine kinase inhibitors (TKIs) are the mainstay of CML treatment, including imatinib, nilotinib, dasatinib, bosutinib, and ponatinib. Beyond matching patient disease profiles with TKI specificity, differences in the efficacy and toxicity profiles and a patient's comorbid risk factors should be considered when selecting the most appropriate agent. Our objectives are to review the incidence and severity of cardiovascular, metabolic, and pulmonary disorders associated with these TKIs, highlighting differences in adverse event profiles, suggested risk-mitigation strategies, and guidance for TKI selection in different settings. Patients receiving TKI agents for CML should be monitored for signs and symptoms of toxicity throughout therapy. Preemptive assessment, early toxicity recognition, and prompt management of cardiovascular, metabolic, and pulmonary toxicities can minimize treatment-limiting complications and improve outcomes in patients with CML.
Introduction
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm driven by constitutive activation of the BCR-ABL1 oncogene [1, 2] . The incidence of CML increases with age and is estimated to occur in 1.75/ 100,000 people in the United States [3] . Tyrosine kinase inhibitors (TKIs) are the mainstay of treatment for CML [4, 5] . In fact, it is projected that 181,000 patients will have CML by 2050 [6] . Currently, 5 TKIs are approved by the US Food and Drug Administration for treating patients with chronic-phase CML: imatinib, nilotinib, dasatinib, bosutinib, and ponatinib [7] [8] [9] [10] . Though imatinib is considered the gold standard frontline CML therapy, a substantial proportion of patients develop resistance or intolerance to this drug [11] . In addition to imatinib, nilotinib and dasatinib are also indicated for first-line treatment of CML [9, 10] , and bosutinib is indicated in patients with resistance or intolerance to prior TKI therapy [8] . Ponatinib is specifically used in patients with T315I-positive CML and others for whom no other TKI therapy is appropriate [7, 11] .
The safety of chronic TKI use is especially important because patients with CML may need lifelong TKI treatment [4, 6] . Although most adverse events (AEs) initially occur early in the course of treatment [12] [13] [14] [15] , the onset of some toxicities, including clinically significant cardiovascular and pulmonary toxicities, may be delayed months, or even years, after the start of therapy [16] . The spectrum of potential cardiovascular, metabolic, and pulmonary toxicities associated with TKI treatments range from the chronically problematic to the potentially life-threatening and include heart failure, QT prolongation, hypertension, thrombosis, peripheral arterial occlusive disease (PAOD), hyperlipidemia, hyperglycemia, pulmonary hypertension, pneumonitis, and pleural effusion.
This article reviews the cardiovascular, metabolic, and pulmonary toxicities observed in patients with CML treated with TKIs and discusses current evidence and conventional wisdom for monitoring, evaluating, and managing such complications.
Methods

Search strategy and selection criteria
Searches of PubMed were conducted to identify publications for this review. The following search terms were used: "cardiovascular" or "cardiac" or "vascular" or "pulmonary" or "pleural" or "metabolic" and "chronic myeloid leukemia" and "tyrosine kinase inhibitor." Details of the search strings used can be found in the Supplementary materials.
Comparisons of clinical trials
It is important to recognize that comparisons of clinical trials are limited by differences in the design and conduct of the trials, particularly when comparing toxicities, as these may be confounded by patient baseline characteristics and risk factors. Thus, the inclusion and exclusion criteria of the patient populations studied should be considered when evaluating outcomes. For example, in the phase 3 ENESTnd trial of nilotinib in patients with newly diagnosed CML, patients with existing cardiac dysfunction were excluded, so it is likely that the population studied was at a lower risk of cardiovascular events than the general population [17] [18] [19] . Similarly, in two large clinical trials of bosutinib in patients with previously treated or newly diagnosed CML, patients were excluded if they had a history of clinically significant or uncontrolled cardiac disease [20] .
In the phase 3 DASISION trial of dasatinib in patients with newly diagnosed CML, patients were excluded if they had uncontrolled or serious cardiovascular disease, but patients with certain cardiovascular risk factors (eg, hypertension, angina) were eligible to enroll [21] . Conversely, in the PACE trial of ponatinib in previously treated patients, most of whom had CML, patients with a history of certain cardiovascular events (eg, ischemic disease, venous thromboembolism) or with cardiovascular risk factors (eg, hypertension, hypercholesterolemia) were included, potentially increasing the likelihood of further events on study [22] . Therefore, comparisons of the incidence and severity of the cardiovascular, metabolic, and pulmonary toxicities discussed here should be treated with some caution. In addition, the frequency of AEs reported in clinical trials may not reflect the incidences of these AEs in clinical practice. Consequently, where available, we have included observations from real-world evidence as well as clinical trials.
Results
Cardiac disorders
Heart failure
Heart failure is characterized by dyspnea, fatigue, and fluid retention, including pulmonary edema, peripheral edema, or both [23] . The relationship between TKIs and heart failure was first determined in a preclinical study, which showed that imatinib led to left ventricular function deteriorations in mice [24] . These findings prompted assessment of heart failure associated with TKIs in clinical trials.
In an analysis of 1276 patients with CML, acute lymphoblastic leukemia (ALL), or acute myeloid leukemia who received imatinib for a median follow-up period of 47 months, the incidence of new-onset congestive heart failure was 1.7% (22 patients) [25] . However, patients received imatinib at doses that were substantially lower than those used in the mouse study [24] . The incidence of congestive heart failure associated with imatinib increased with age: 0.3% in patients aged 45 to 55 years, 1.7% in those aged 56 to 65 years, 2.8% in those aged 66 to 75 years, and 9.3% in those aged 76 to 85 years [25] . Similar results were observed in the Framingham Heart Study, which evaluated risk for developing congestive heart failure in the general population and reported increasing risk of this toxicity with age in both men (5-year risk of 0.2% at index age 40, 0.8% at 50, 1.3% at 60, 4.0% at 70, and 8.3% at 80 years) and women (0.1% at age 40, 0.1% at 50, 0.7% at 60, 2.2% at 70, and 7.8% at 80 years) [26] .
Heart failure is especially a concern for patients taking ponatinib. The US prescribing information for ponatinib has a black-box warning for heart failure, noting an occurrence rate of 8% [7] . In contrast, a study of 499 patients with CML demonstrated cardiac failure related to ponatinib in only 1% to 3% of patients [22] . However, findings from a recent study demonstrated that dose intensity of ponatinib was associated with cardiac failure [27] .
From an analysis of 570 patients taking bosutinib as second-, third-, or fourth-line therapy for CML or advanced-phase leukemia, heart failure was reported in 4.4% of patients [20] . In patients undergoing first-line treatment, heart failure was reported in 0.8% of patients taking bosutinib (n = 248), the same percentage reported in patients taking imatinib (n = 251) [20] . Similarly, congestive heart failure or cardiac dysfunction was reported in 2% of 258 patients with CML treated with dasatinib after both 1-year and a 5-year follow-up periods [10] . With nilotinib, a retrospective analysis showed that 3 of 81 patients who were followed for a median of 44 months had heart failure [28] .
Although heart failure may not be a very common AE associated with TKIs (with the exception of ponatinib), it is a serious complication. As such, patients taking a potentially cardiotoxic TKI should be monitored for signs of heart failure [29, 30] . Cardiac monitoring is required for patients taking ponatinib, is recommended for dasatinib, nilotinib, and bosutinib, and is unnecessary for imatinib [16] . In patients who do develop heart failure, a patient's cancer status does not affect how heart failure should be managed [23, 29] . Recommended therapies for heart failure are based on current guidelines, which take into account the patient's stage in the development of heart failure ( Table 1) [7] [8] [9] [10] 16, 23, 29, [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] .
QT prolongation
QT prolongation is associated with potentially sudden and fatal arrhythmias, including torsades de pointes (TdP) [42] . Most TKIs indicated for CML have negligible clinically relevant effects on the QT interval [43, 44] . However, the US prescribing information for dasatinib advises caution in patients at increased risk for QT prolongation [10] , and nilotinib is associated with QT prolongation and related sudden death [28, 45] , resulting in a black-box warning in the US prescribing information for these events [9] .
A review of the cardiovascular safety of TKIs found clinical evidence for an effect of nilotinib when used as a second-line agent on corrected QT (QTc) interval, whereas evidence was equivocal for dasatinib, inconclusive for imatinib, and negative for bosutinib [43, 45] . An initial study of nilotinib found that the QT interval was prolonged by 5 to 15 ms without evidence of TdP [46] . Despite these relatively small QT interval changes, sudden cardiac death was reported in 0.3% of patients, which prompted the black-box warning for nilotinib [9, 47] . In a 5-year follow-up of patients with CML who received first-line nilotinib (n = 556) or imatinib (n = 280), no episodes of TdP, ventricular flutter, ventricular tachycardia, ventricular fibrillation, or sudden death were reported [48] . However, patients with impaired cardiac function or receiving medication known to prolong the QT interval were excluded from this trial [18] . Although QT interval prolongation has been reported with dasatinib, the maximum mean change in QT interval was only 7 to 13 ms [10] , and no QT interval changes were reported in the 6-year follow-up of a phase 3 trial of dasatinib in 670 patients with imatinib-resistant or intolerant CML (median 29 months of therapy) [49] . According to the US prescribing information for dasatinib, 22 patients (1% of all treated patients) had clinically relevant QTc prolongation of > 500 ms in clinical trials [10] . In a phase 1 study, no significant clinical changes in QTc interval were found in an analysis of QT effects of ponatinib in 39 patients with refractory hematologic malignancies (primarily CML) [44] . Before commencing TKI therapy, patients should be assessed for risk of QT prolongation based on their medical history and use of concomitant medications that can prolong the QT interval, such as antiarrhythmics, certain antibiotics, antifungals, antihistamines, tricyclic antidepressants, and cytochrome P450 3A4 (CYP3A4) inhibitors (Table 1) [9, 10, 29, 42] . Low potassium or magnesium levels should be corrected before patients commence nilotinib or dasatinib treatment [9, 10] , and patients should undergo regular monitoring and correction of their serum potassium and magnesium concentrations during treatment [29, 42] . Patients scheduled to receive nilotinib should have electrocardiogram (ECG) monitoring at baseline, 7 days after nilotinib initiation, and periodically as clinically needed, including after dose adjustments [9, 39] . Patients should avoid food for 2 h before and 1 h after a nilotinib dose because food (especially with a high fat content) can substantially prolong the QT interval [9] . If patients have a QTc interval > 480 ms during nilotinib therapy, the drug should be withheld, electrolytes should be corrected if necessary, and concomitant medications should be reviewed. If the QTc interval using the Fridericia's correction (QTcF = QT/RR 1/3 ) [50] returns to < 450 ms and ≤20 ms of baseline, nilotinib therapy should be resumed at the prior dose within 2 weeks. If QTcF is 450 to 480 ms after 2 weeks, the nilotinib dose should be reduced to 400 mg once daily, and if QTcF returns to > 480 ms after the dose reduction, nilotinib should be discontinued [9] .
Venous thrombosis and vascular disorders 4.2.1. Hypertension
If not appropriately managed, hypertension can lead to severe cardiovascular complications such as stroke, myocardial infarction, renal dysfunction, and death [33] . Among TKIs, hypertension is associated primarily with inhibition of the vascular endothelial growth factor receptor (VEGFR) and may occur as early as 3 to 4 days after treatment initiation [43] . This is thought to be a downstream consequence of VEGFR-mediated inhibition of angiogenesis, effects on vasodilators and vasoconstrictors (including decreased production and/or bioavailability of nitric oxide), and changes in glomerular function (via microvascular rarefaction), which lead to increased vascular tone and peripheral resistance [43, [51] [52] [53] . Hypertension is especially a concern in patients taking ponatinib [54] and appears to be associated with increased ponatinib dose intensity [27] . In clinical trials, 67% of 449 patients treated with ponatinib experienced hypertension, and 8 patients (2%) had symptomatic hypertension as a serious AE [7] . In ponatinib-treated patients with baseline blood pressure (BP) < 140/90 mm Hg, 78% of 282 patients experienced hypertension, 49% developed Stage 1 hypertension (systolic BP ≥ 140 mm Hg or diastolic BP ≥ 90 mm Hg), and 29% developed Stage 2 hypertension (systolic BP ≥ 160 mm Hg or diastolic BP ≥ 100 mm Hg) [7] . In clinical trials of other TKIs, the incidence of hypertension was considerably lower. In a 5-year follow-up of front-line nilotinib, hypertension was reported in 8.3% to 10.4% of 556 patients with CML [48] . In 818 patients with CML or ALL treated with bosutinib as first-line or later therapy, 7.8% had hypertensionrelated AEs, and most patients with a history of hypertension did not experience new events [20] . Hypertension with dasatinib or imatinib has been reported in < 10% and 4% of patients, respectively [10, 31] .
Before commencing TKI therapy, patients should be assessed for increased risks for hypertension and associated adverse patient characteristics and comorbidities, including race, age, underlying cardiovascular disease, diabetes, and kidney disease (Table 1) [33, 51] . Particularly in patients receiving ponatinib, BP should be monitored throughout treatment, with more frequent assessments when ponatinib is first initiated [51] . If hypertension cannot be controlled, the ponatinib dose should be interrupted or reduced, or treatment should be discontinued [7] . Treatment guidelines for the management of hypertension, issued by the Eighth Joint National Committee, provide a hypertension management algorithm and recommend that the goals for systolic and diastolic BP should be < 150/90 mm Hg for adults aged ≥60 years and < 140/90 mm Hg for adults aged < 60 years [33] . Angiotensin system inhibitors (eg, ace inhibitors and angiotensin II receptor blockers) and dihydropyridine calcium channel blockers (eg, felodipine or amlodipine) are preferred treatment options for hypertension associated with anti-VEGF therapy because of their high peripheral vascular selectivity [53] . Nondihydropyridine calcium channel antagonists should be avoided because these agents inhibit CYP3A4, through which some TKIs are metabolized [53] .
Venous thrombosis
Venous thrombosis is associated with an increased risk of arterial cardiovascular events, including myocardial infarction, stroke, and peripheral vascular disease [55] . Venous thrombosis is of particular concern in patients receiving ponatinib, which has a black-box warning for this phenomenon [7] . In a phase 2 study of ponatinib, venous thromboembolic events were reported in 5% of patients, with 3% of these events considered serious [56] . In a subsequent randomized phase 3 study of 307 patients, a serious venous thromboembolic event was reported in only 1 patient receiving ponatinib [7, 57] .
Patients receiving ponatinib should be monitored for venous thromboembolism [7] . Ponatinib dose modification or discontinuation should be considered in patients who develop serious venous thromboembolism [7] . Based on current guidance on the treatment of cancerassociated venous thromboembolism, patients with these events should be treated with low molecular weight heparin for ≥6 months [58] .
Arterial vascular events
Arterial vascular events may lead to serious cardiovascular conditions, including myocardial infarction, stroke, and sudden death [55] . Historically, arterial vascular events were not commonly associated with dasatinib treatment. However, recent findings suggest otherwise. After 5 years of follow-up in patients with newly diagnosed chronicphase CML from the DASISION study of dasatinib, arterial ischemic events were reported in 5% of 258 patients receiving dasatinib compared with 2% of 258 patients receiving imatinib. Of these, 7 of 10 cardiovascular ischemic events occurred within 12 months of starting dasatinib therapy. Two patients in the dasatinib group had a transient ischemic attack (compared with none in the imatinib group), and 2 patients in the imatinib group had PAOD [21] .
Compared with imatinib or dasatinib, an increased risk for arterial thrombosis has been observed with nilotinib, which appears to be due to its effects on platelet and endothelial activation, thrombus formation, and atherogenic potential [59, 60] . In a retrospective analysis of 105 patients receiving second-line dasatinib or nilotinib in a real-world setting, 2 patients (4%) and 6 patients (11%), respectively, had vascular events, with a time to onset of 19 to 22 months with dasatinib and 6 to 69 months with nilotinib. Two of the patients who received nilotinib died, one from myocardial infarction and one from ischemic stroke. The other events in the nilotinib group were atrial fibrillation (2 patients), PAOD (1 patient), and myocardial infarction (1 patient). In the dasatinib group, one patient each had myocardial infarction and ischemic stroke. However, 5 of the 6 patients in the nilotinib group and 1 of the 2 patients in the dasatinib group had cardiovascular risk factors at baseline [61] . Additionally, in a recent meta-analysis, the risk of vascular occlusive events increased significantly with dasatinib, nilotinib, and ponatinib, but not bosutinib, when compared with imatinib [62] . Several reports have associated nilotinib therapy with accelerated atherosclerosis [36, [63] [64] [65] [66] [67] . In a study of first-line nilotinib, after a median follow-up of 75 months, 11 (15%) of 73 patients experienced atherosclerotic events, including 4 patients with PAOD, 2 with carotid stenosis, 1 with angina pectoris, and 1 with atrial fibrillation [68] . The median time from initiation of nilotinib therapy to development of these AEs was 42 months, and atherosclerotic AEs were significantly more common in patients ≥65 years old versus younger patients [68] .
The US prescribing information for ponatinib has a black-box warning for arterial occlusion (including fatal myocardial infarction, stroke, stenosis of large arterial vessels of the brain, severe peripheral vascular disease, and the need for urgent revascularization procedures), which has been reported in at least 35% of patients and can occur within 2 weeks of starting ponatinib treatment [7, 54] . In a multivariate analysis of 4-year follow-up data from 3 ponatinib trials (n = 671), after a median 7.4 months of treatment, arterial occlusive events (cardiovascular, cerebrovascular, and peripheral vascular events) were reported in 102 patients (15%) and were significantly associated with dose intensity, older age, and prior history of ischemic disease. Specifically, cardiac failure, in 38 patients (6%), and cardiovascular events, in 58 patients (9%), had strong associations with dose intensity. Cerebrovascular events occurred in 30 patients (4%) [27] . A comparative study in 307 patients found that 7% of ponatinib patients and 2% of imatinib patients had arterial occlusive events (cardiovascular, cerebrovascular, or peripheral vascular), which were serious in 6% of ponatinib patients (4 patients with cardiovascular events, 3 with cerebrovascular events, and 3 with peripheral vascular events) and 1% of imatinib patients (1 patient with a cerebrovascular event) [69] . In a study of ponatinib in heavily pretreated patients, after a median of 28 months of follow-up, arterial thrombotic events were reported in 19% of 449 patients and were serious in 14%, including cardiovascular (10%), cerebrovascular (7%), and peripheral vascular events (4%) [56] . At 4 years, the cumulative incidence of arterial occlusive events had increased to 29%, resulting in death in 3 patients [70] .
When considering PAOD specifically, based on data from randomized trials comparing second-generation TKIs with imatinib, PAOD risk appears highest with ponatinib followed by nilotinib, whereas the risk with other TKIs is relatively low [16, 19, 48, 61, 69, [71] [72] [73] . PAOD, including fatal mesenteric artery occlusion and life-threatening peripheral arterial disease, has been reported in up to 12% of patients treated with ponatinib [7] . In a pooled analysis of 671 patients from 3 ponatinib clinical trials, peripheral vascular events were reported in 35 patients (5%) after a median 7.4 months of treatment [27] . In a retrospective cohort analysis of 3 trials in patients with newly diagnosed CML, 7 of 556 patients who received nilotinib and 2 of 1302 patients who received imatinib had PAOD events, and the exposure-adjusted relative risk for PAOD was 10.8 for patients receiving nilotinib compared with patients receiving imatinib. However, 8 of these 9 patients had pre-existing baseline cardiovascular risk factors [72] . In a prospective analysis of 159 patients receiving first-line nilotinib or imatinib, 1 patient receiving first-line nilotinib had clinically manifest PAOD (0 events with first-line imatinib). However, comparing total drug exposure in these 2 treatment groups, the relative risk for PAOD as detected by an abnormal ankle-brachial index was 10.3 for nilotinib compared with imatinib [36] . The nilotinib US prescribing information includes a warning about PAOD, and reports a 2.9% to 3.6% incidence in patients treated with nilotinib. With ponatinib and nilotinib, PAOD is usually reported within the first 48 months of treatment, but the duration to onset can range from 4 months to 5 years [16] .
Evidence-based guidelines, such as those from the American College of Chest Physicians, provide detailed recommendations for the prevention and management of thrombosis [34, 35] . Prevention and management strategies for PAOD include assessing the patient's cardiovascular risk before and during TKI treatment, including palpation of peripheral pulses (Table 1 ) [16] . Ankle-brachial index should be measured at baseline and during follow-up visits [16, 32] , and prophylactic treatment with a daily dose of aspirin or clopidogrel may be warranted [74, 75] . Managing risk factors for PAOD, including hypercholesterolemia, hypertension, diabetes, and smoking, is also recommended [74, 75] . For more serious PAOD that would require interventional revascularization procedures, reducing the dose of the TKI or switching to another TKI is advisable [36] .
Metabolic disorders 4.3.1. Hyperlipidemia
Hyperlipidemia is a major risk factor for cardiovascular disease and is a common AE associated with nilotinib therapy [9, 76] . In 168 patients receiving nilotinib, dasatinib, or imatinib as their first or subsequent line of therapy, total cholesterol and low-density lipoprotein cholesterol (LDL-C) increased significantly with nilotinib compared with imatinib [76] . In a study of 27 patients, total cholesterol and LDL-C levels significantly increased from baseline within 3 months of nilotinib treatment [77] . At the 5-year follow-up of a trial in 836 patients with newly diagnosed CML receiving nilotinib or imatinib, clinically relevant elevations in total cholesterol (> 7.75 mmol/L) and LDL-C (> 4.91 mmol/L) were more common with nilotinib 300 mg or 400 mg twice daily than with imatinib (total cholesterol, 16% and 15% vs 1%; LDL-C, 23% and 22% vs 4%, respectively) [48] . These findings indicate a pathophysiologic mechanism for the development of vascular events during nilotinib treatment [78] . Hyperlipidemia is not commonly reported with other TKIs [7, 8, 10, 31] .
Management of hyperlipidemia is important to minimize the risk of related cardiovascular events (Table 1 ). In patients treated with nilotinib, lipid profiles should be obtained before therapy, periodically during the first year of therapy, and at least annually in patients undergoing chronic therapy [9] . In addition, patients should be educated on appropriate lifestyle modifications, including exercise, avoiding tobacco, and adhering to a healthy diet [37] . According to treatment guidelines for hypercholesterolemia, a statin is recommended in patients with clinical atherosclerotic cardiovascular disease, patients with LDL-C levels of ≥190 mg/dL, patients aged 40 to 75 years with diabetes who have LDL-C levels of 70-189 mg/dL, and patients without diabetes aged 40 to 75 years who have an estimated 10-year atherosclerotic cardiovascular disease risk of ≥7.5% and who have LDL-C levels of 70 to 189 mg/dL [37] . For patients who require statin therapy, a statin that is not metabolized by the CYP3A4 isoenzyme, such as pravastatin or rosuvastatin [79] , is preferred to avoid potential drug-drug interactions with nilotinib [9] or ponatinib [7] .
Hyperglycemia
Hyperglycemia is another cardiovascular risk factor that is associated with increased mortality [80] The incidence of hyperglycemia is generally uncommon (< 1% of patients) with all TKIs except for nilotinib, which is associated with increases in fasting plasma glucose levels and other glycometabolic abnormalities [9, 10, 31, 76] . Five-year followup data from a trial in 836 patients with newly diagnosed CML receiving nilotinib or imatinib showed that approximately 50% of patients treated with nilotinib had worsening or newly occurring elevations in glucose levels, compared with 31% of patients receiving imatinib. Furthermore, grade 3/4 glucose elevations occurred in 7% and < 1% of patients, respectively [48] . Hyperglycemia was usually observed within the first 2 to 3 weeks of nilotinib treatment, whether first or second line, but has been reported within 7 days [16, 81] . Despite the frequency of hyperglycemia with nilotinib, it appears to be reversible and manageable, without serious clinical consequences [82] .
Detailed evidence-based guidelines are available for the management of hyperglycemia and diabetes (Table 2 ) [38] . For patients scheduled to receive nilotinib therapy, glucose levels should be assessed before initiating treatment, monitored periodically during the first year of therapy, and assessed at least yearly with chronic therapy [9] . In patients taking other TKIs, there are no specific recommendations for monitoring glucose levels, except monitoring should be undertaken as clinically necessary [7] [8] [9] [10] 16] . Patients with preexisting diabetes who receive a TKI, particularly nilotinib, may require glucose monitoring more frequently [16] . If treatment for hyperglycemia is warranted, general management guidelines for diabetes are recommended for patients with CML [38] .
Pulmonary disorders 4.4.1. Pulmonary hypertension
Among the TKIs used to treat CML, dasatinib has the highest incidence of pulmonary toxicities, including pulmonary hypertension (PH) [16] . PH is a severe and progressive cardiopulmonary disease associated with high morbidity and mortality [83] , and is defined as an increase in mean pulmonary artery pressure of ≥25 mm Hg at rest [84] . The World Health Organization has divided PH disorders into 5 groups based on etiology. Group 1 (pulmonary arterial hypertension) includes cases attributed to certain medications; individuals in this diagnostic group have a very poor prognosis if left untreated [85] [86] [87] . There have been case reports of PH developing in patients receiving dasatinib and then resolving or improving with cessation of TKI therapy [84, 88, 89] . In registry data, the overall incidence of PH with dasatinib was low (< 1%) [84] . In the DASISION trial, PH was suspected based on echocardiography findings in 5% of patients receiving dasatinib, but only 1 patient underwent right heart catheterization and PH was not confirmed [21] . Cases of PH have been reported with ponatinib [90] and imatinib [21] as well, although rarely, and prior treatment with dasatinib makes attribution challenging in the ponatinib cases. The increased incidence of PH with dasatinib compared with other TKIs may be the result of off-target TKI effects due to this agent's relatively nonselective nature [88, 91] . Patients with PH present with fatigue and dyspnea in a relatively nonspecific fashion, but the presence of peripheral edema or jugular venous distention suggests PH. The median reported onset of PH after initiation of dasatinib treatment is 34 months, though there is considerable variability (range 8-48 months) [84] . Echocardiography is useful to aid diagnosis; if imaging suggests potentially elevated pulmonary pressures or signs of right-sided heart failure, evaluation by a PH specialist is strongly recommended. Individuals with suspected PH may undergo right heart catheterization to confirm diagnosis [83, 84] .
Several evidence-based guidelines are available for the management of PH [83, 92] , and specifically for patients with CML undergoing TKI treatment (Table 3 ) [16] . Dasatinib should be permanently discontinued in patients who develop confirmed PH [10] . In general, PH regresses with cessation of TKI therapy, but it can be fatal. Although endothelin receptor antagonists and calcium channel blockers improve pulmonary pressures in patients with PH, it is unclear whether they offer any improvement over discontinuing dasatinib [84] . Patients considered for dasatinib therapy should be assessed for preexisting cardiopulmonary disease before treatment and should be monitored for new symptoms during treatment.
There have been no reports of PH with nilotinib, and several patients have been successfully treated with nilotinib after dasatinib-related PH [84, 89] . Further TKI therapy should be approached in such patients on a case-by-case basis with careful risk/benefit assessment.
Pleural effusion
Unilateral or bilateral pleural effusions are a potential complication associated with all TKIs, although fewer cases have been reported with imatinib or nilotinib compared with other agents [16, 93] . Dasatinib is associated with a notably higher incidence of pleural effusion. In a comparative trial of dasatinib versus imatinib in 519 treatment-naïve patients, at the 5-year follow-up, pleural effusion was more frequent with dasatinib (28% of patients) than with imatinib (1%), and was more prevalent in older patients [21] . In a retrospective study in 105 patients receiving second-line therapy, pleural effusion was reported in 26% of patients receiving dasatinib, but only 2% of patients receiving nilotinib [61] . In 449 patients receiving ponatinib therapy for CML or ALL, 7% of patients had pleural effusion, with 1% judged to be serious [7] . In 288 patients with CML receiving second-line bosutinib, pleural effusion was reported in 4% of patients by 2 years [94] . Similarly, pleural effusion was observed in 4% of 248 patients with newly diagnosed CML receiving first-line bosutinib, but only 1% of 251 patients Table 2 Monitoring and managing metabolic toxicities associated with TKIs [7] [8] [9] [10] 16, 23, 29, [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] . 
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receiving imatinib [71] . The median time to onset of pleural effusion was 10 months after initiating first-line dasatinib and 5 to 11 months after commencing second-line treatment; however, in a real-world analysis, the median time to onset was 33 months [16, 61] . Risk factors for pleural effusion with dasatinib include higher dose, longer duration of treatment, twice-daily dosing, older age, and a history of cardiac disease, hypertension, or hypercholesterolemia [74, 94] . All patients receiving TKI treatment, especially those treated with dasatinib or with known risk factors, should be monitored for symptoms of pleural effusion, including rapid weight gain, progressive dyspnea, or nonproductive cough [16, 39] . If physical examination is suggestive (dullness to percussion or focally diminished breath sounds), a chest radiograph should be performed (Table 3) [16, 39] . Depending on the size of the effusion, burden of symptoms, or index of suspicion for possible pleural space infection, thoracentesis may be performed for both diagnostic and therapeutic purposes [16, 39] . Pleural fluid is typically exudative with lymphocyte predominance [39] . Depending on the size of the effusion and circumstance, therapeutic options include TKI dose reduction or discontinuation (either temporarily or permanently), diuretics, corticosteroids, or thoracentesis [16, 39] . Rarely, repeat thoracentesis or pleurodesis are employed for treating persistent pleural effusions, but the value of this therapeutic option remains unclear; for persistent or recurrent symptomatic effusions, TKI therapy may need to be discontinued [39] .
Pneumonitis
Clinically significant pneumonitis is rarely observed with TKI therapy overall but has been reported in CML patients treated with dasatinib (< 10% of patients) and imatinib (< 1%) [10, 31, 93, 95] . Both hypersensitivity pneumonitis and interstitial pneumonitis have been described [16, 95] . There has been considerable variation in time to onset. Pneumonitis reported with imatinib occurred at a median of 49 days (range, 10-282 days) after initiation of treatment, and respiratory symptoms associated with dasatinib occurred at a median of 229 days (range, 20-510 days) after treatment initiation [41, 93] . In 40 patients receiving dasatinib therapy for chronic-phase CML after primary or secondary imatinib resistance or imatinib intolerance, 23% developed lung abnormalities [93] . These occurred with a range of clinical symptoms, both lung related (eg, chest pain, dyspnea) and nonlung related (eg, myalgia, arthralgia), and diverse combinations of findings were found on high-resolution computed tomography, such as "ground-glass" opacities, septal thickening, unilateral or bilateral pleural effusions, transient chylothorax, mosaic pattern, and/or alveolar condensation [93] . In some cases, pleural fluid analysis revealed lymphocytic or neutrophilic exudate, and bronchoalveolar lavage fluid analysis primarily revealed lymphocytic accumulation [93] . These findings underscored the nonspecificity of symptoms. Some cases have been associated with fever [93] , although in such cases respiratory infection could have been the cause. Pneumonitis has occurred too infrequently with TKIs thus far to determine risk factors. As with most drug-related pneumonitis, appearance on chest radiograph or computed tomography scan can be variable and nonspecific, but may prompt further evaluation and provide a means to gauge improvement [41, 93] . Bronchoalveolar lavage plays an important role in excluding alternative diagnoses (particularly infections); it is not clear whether lung biopsy adds significant diagnostic value. Serial imaging may assist in monitoring for resolution.
Much of the information regarding management of pneumonitis during TKI therapy comes from case reports of events observed in dasatinib-or imatinib-treated patients [16, 93, 95] . In these reports, most patients improved following discontinuation of TKI therapy, with complete resolution in the majority of cases [16, 93, 95] . Concomitant treatment with steroids may be warranted to help manage pneumonitis or to avoid TKI therapy cessation, but their benefit remains uncertain. If more than mild pneumonitis is diagnosed with TKI therapy, dose reduction or cessation of the offending agent in favor of alternative therapy with nilotinib or bosutinib should be considered [16] . However, rechallenging with TKI therapy after pneumonitis should be approached on a case-by-case basis because toxicity may recur.
Selecting TKI treatment
Each TKI indicated for patients with CML has a distinct toxicity profile, with specific cardiovascular, pulmonary, and metabolic AEs Table 3 Monitoring and managing pulmonary toxicities associated with TKIs [7] [8] [9] [10] 16, 23, 29, [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] .
AE
Monitoring Recommendations Prevention and Management Recommendations
Pulmonary hypertension
• Assess for preexisting cardiopulmonary disease before TKI treatment, particularly to determine suitability for DAS
• Consider in patients with new dyspnea, fatigue, or peripheral edema • Obtain echocardiogram in patients with dyspnea and normal chest x-ray
• If echocardiogram suggests pulmonary hypertension, refer to pulmonary hypertension specialist for consideration of pulmonary artery catheterization to confirm diagnosis and to comment on role for pulmonary hypertension-specific therapies
• Permanently discontinue TKI therapy in patients who develop pulmonary hypertension Pleural effusion
• Risk factors include older age, higher total dose or twice-daily TKI dosing, prolonged duration of therapy, and history of cardiac disease, hypertension, or hypercholesterolemia
• Consider in patients with new dyspnea, cough, or chest discomfort • Obtain chest x-ray in patients with new or progressive pulmonary symptoms; presence of fluid can be confirmed with bedside ultrasonography 
B.C. Medeiros et al.
Blood Reviews 32 (2018) 289-299 Table 4 Comparison of TKIs [7] [8] [9] [10] 31, [96] [97] [98] [99] [100] . • Patients with preexisting cardiopulmonary disease AP = accelerated phase; BC = blast crisis; BID = twice daily; CHF = congestive heart failure; CML = chronic myeloid leukemia; CP = chronic phase; PAH = pulmonary arterial hypertension; Ph = Philadelphia chromosome; QD = once daily; TKI = tyrosine kinase inhibitor.
TKI
B.C. Medeiros et al.
Blood Reviews 32 (2018) [289] [290] [291] [292] [293] [294] [295] [296] [297] [298] [299] ( Table 4) [7] [8] [9] [10] 31, [96] [97] [98] [99] [100] . Because imatinib, dasatinib, and nilotinib are indicated as first-line treatments for CML [9, 10, 31, [96] [97] [98] , selection of a particular TKI may depend on the individual patient's medical history and baseline risk factors for certain AEs. Similarly, when second-line therapy is indicated, AEs that the patient has experienced with prior TKIs, as well as their medical history and risk factors for AEs, all influence the selection of the second-line agent.
Case examples
A woman aged 50 years was referred for treatment after a routine checkup from her primary care physician revealed complete blood count results consistent with Ph + chronic-phase CML. The patient had a low-risk Sokal score, no family history for hematologic disease, and a medical history for poorly controlled diabetes mellitus. The patient was initiated on imatinib 400 mg once daily due to the patient's low-risk score and the lower cost of generic imatinib compared with branded dasatinib or nilotinib. After poor response with 3 months of imatinib treatment (BCR-ABL1 transcript level > 10%), dasatinib 100 mg once daily was prescribed. Dasatinib was chosen over nilotinib due to the patient's history of uncontrolled diabetes. After 3 months of treatment with dasatinib, a major molecular response was observed.
A 22-year old man presented with chief complaints of chronic fatigue and increasing weight loss. Laboratory results revealed a total white blood cell count of 30,000 cell/μL and moderate normochromic anemia. Bone marrow findings showed BCR/ABL rearrangement and were positive for Ph chromosomes. The patient is a chronic smoker and has a medical history of asthma. The patient was diagnosed with chronic-phase CML. Using the Sokal score, the patient was classified as high risk. Based on the patient's young age and high-risk CML, dasatinib or nilotinib were considered for first-line treatment because they are more potent than imatinib. Due to the patient's risk factors for pleural effusion, nilotinib 300 mg twice daily was prescribed.
Discussion
Standard therapy for patients with chronic-phase CML is a TKI. However, there are differences in the safety profiles of each agent with regard to cardiovascular, metabolic, and pulmonary toxicities, some of which occur more often with chronic TKI treatment. Moreover, because the median age of diagnosis for CML is 64 years [101] , these older patients may have comorbidities and risk factors that increase the likelihood of TKI-mediated toxicities during long-term treatment.
The different target profiles of these TKIs are believed to contribute to their distinct toxicity profiles [11] . All TKIs inhibit a range of kinases, but to varying degrees. Compared with most of the other TKIs, dasatinib has a higher inhibitory action against Src-family kinases, Bruton's tyrosine-protein kinase, and platelet-derived growth factor receptor alpha (PDGFRα); bosutinib has a higher inhibitory action against Src-family kinases; and ponatinib has a higher inhibitory action against PDGFRα, c-Kit, and VEGFR-2 [7] [8] [9] [10] [11] 31] . Unlike the other TKIs, bosutinib demonstrates minimal inhibitory activity against c-Kit and PDGFR, which may account for the lower incidence of cardiovascular toxicities with bosutinib compared with the other TKIs [11, 20] .
Before initiating TKI therapy, each patient should be assessed for cardiovascular, metabolic, and pulmonary AE risk factors, which, together with an understanding of the toxicity profiles of each TKI, will help to determine the most appropriate agent. Regular monitoring and early recognition of AEs during treatment will help to mitigate any toxicities [16] , and aggressive risk factor modification with the initiation of prophylactic treatments can prevent unwanted cardiovascular events. Appropriate treatment choice along with the prevention and management of toxicities associated with TKIs can help prevent premature cessation of therapy and optimize long-term outcomes in patients with CML.
Practice points
• The tyrosine kinase inhibitors (TKIs) imatinib, nilotinib, dasatinib, bosutinib, and ponatinib are the mainstay of treatment for patients with chronic myeloid leukemia (CML)
• TKIs have differing safety profiles, particularly with regard to cardiovascular, metabolic, and pulmonary toxicities
• Before initiating TKI therapy, patients should be assessed for cardiovascular, metabolic, and pulmonary risk factors
• During TKI therapy, patients should be monitored for these toxicities, as prompt management of these events can minimize treatment-limiting complications and improve outcomes in patients with CML
Research agenda
• Evaluation of safety profiles of the available tyrosine kinase inhibitors (TKIs) imatinib, nilotinib, dasatinib, bosutinib, and ponatinib, for the treatment of chronic myeloid leukemia (CML)
• Comparison of cardiovascular, metabolic, and pulmonary toxicity profiles of these TKIs
• Review of clinical practice guidelines for specific cardiovascular, metabolic, and pulmonary toxicities
• Recommendations for assessment of patients before and during TKI therapy to minimize these toxicities and improve outcomes in patients with CML
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